QIAGEN N.V.

Money Moves

Target company; boards recommend the offer

Swedish buyout firm EQT Private Equity agreed to buy Dutch molecular testing company QIAGEN for €46.50 a share in cash, valuing it at about $12.1 billion including roughly $1.1 billion of net debt. The price is 40.3% above QIAGEN's €33.15 close on July 8, the last trading day before reports of private equity interest surfaced.

Updated Oct 23